Journal Article

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera

Gotlib, Jason, Nath, Uttam K., Verstovsek, Srdan, Yacoub, Abdulraheem, Palmer, Jeanne, Ritchie, Ellen K., Ginzburg, Yelena Z., Khanna, Sarita, Kremyanskaya, Marina, Gupta, Suneel, Molina, Arturo, Valone, Frank H., Kuykendall, Andrew T., Pemmaraju, Naveen, Pettit, Kristen, Saks, Samuel R., Modi, Nishit B., Gerds, Aaron, Hoffman, Ronald

2024

Overview

Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the availability of iron for erythropoiesis. The safety and efficacy of rusfertide in patients with phlebotomy-dependent polycythemia vera are unknown. In part 1 of the international, phase 2 REVIVE trial, we enrolled patients in a 28-week dose-finding assessment of rusfertide. Part 2 was a double-blind, randomized withdrawal period in which we assigned patients, in a 1:1 ratio, to receive rusfertide or placebo for 12 weeks. The primary efficacy end point was a response, defined by hematocrit control, absence of phlebotomy, and completion of the trial regimen during part 2. Patient-reported outcomes were assessed by means of the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) patient diary (scores range from 0 to 10, with higher scores indicating greater severity of symptoms). Seventy patients were enrolled in part 1 of the trial, and 59 were assigned to receive rusfertide (30 patients) or placebo (29 patients) in part 2. The estimated mean (±SD) number of phlebotomies per year was 8.7±2.9 during the 28 weeks before the first dose of rusfertide and 0.6±1.0 during part 1 (estimated difference, 8.1 phlebotomies per year). The mean maximum hematocrit was 44.5±2.2% during part 1 as compared with 50.0±5.8% during the 28 weeks before the first dose of rusfertide. During part 2, a response was observed in 60% of the patients who received rusfertide as compared with 17% of those who received placebo (P = 0.002). Between baseline and the end of part 1, rusfertide treatment was associated with a decrease in individual symptom scores on the MPN-SAF in patients with moderate or severe symptoms at baseline. During parts 1 and 2, grade 3 adverse events occurred in 13% of the patients, and none of the patients had a grade 4 or 5 event. Injection-site reactions of grade 1 or 2 in severity were common. In patients with polycythemia vera, rusfertide treatment was associated with a mean hematocrit of less than 45% during the 28-week dose-finding period, and the percentage of patients with a response during the 12-week randomized withdrawal period was greater with rusfertide than with placebo. (Funded by Protagonist Therapeutics; REVIVE ClinicalTrials.gov number, NCT04057040.).

• Publisher: Massachusetts Medical Society
• Subject: Blood cancer / Double-Blind Method / Erythropoiesis / Hematocrit / Hematologic Agents - administration & dosage / Hematologic Agents - therapeutic use / Hematology / Hepcidin / Hepcidins - administration & dosage / Hepcidins - therapeutic use / Humans / Injections / Iron / Leukemia / Lymphoma / Neoplasia / Oncology / Patients / Peptides / Peptides - administration & dosage / Peptides - therapeutic use / Phlebotomy / Placebos / Polycythemia / Polycythemia - diagnosis / Polycythemia - drug therapy / Polycythemia - etiology / Polycythemia vera / Polycythemia Vera - complications / Polycythemia Vera - diagnosis / Polycythemia Vera - drug therapy / Statistical analysis / Thromboembolism / Thrombosis / Treatments in Oncology / Tumors